Victrelis (boceprevir) to be discontinued

Victrelis (boceprevir)Victrelis (boceprevir) and Victrelis Triple (Victrelis + pegylated interferon with ribavirin) will be voluntarily discontinued on March 31st, 2016.

The decision to discontinue Victrelis was not based on safety or efficacy findings, but scientific advancements, changes in treatment practices, and a decreased demand for the hep C treatment. Victrelis remains available to those still taking it.

For more information, please contact the Merck Care Program at: 1-866-872-5773.